AACR 2025 IO: Unlocking Desmoplastic Melanoma’s Secrets with Kari Kendra, MD, PhD - Ohio State

Описание: Dive deep into the cutting-edge world of melanoma treatment with this comprehensive video on desmoplastic melanoma, presented at AACR 2025 in Los Angeles by Kari L. Kendra, MD, PhD from The Ohio State University. Uncover the latest immunotherapy breakthroughs that are transforming cancer care, as Dr. Kendra explains why this unique form of melanoma—found in high sun-exposed areas with significant UV damage and a high tumor mutational burden—exhibits such remarkable response rates. This presentation, hosted by a leading expert, reveals the science behind the disease’s inflammatory state and desmoplasia, which are believed to drive its high treatment success.

Follow along as Dr. Kendra breaks down the critical differences between the resectable and unresectable cohorts in this study. Learn how resectable patients, with early-stage or locally recurrent disease, received just three treatments before surgery, achieving an astonishing 57% pathological complete response rate in only nine weeks (0:01:39). Meanwhile, unresectable patients, with distant metastatic disease like lung involvement, underwent longer treatment every three weeks due to the extent of their condition, ultimately reaching an impressive 89% overall response rate over time (0:02:13).
We’ll also examine the treatment challenges, including why most patients stopped after one year instead of the planned two—often due to no clinical evidence of disease and concerns over potential toxicities (0:01:07). Discover the safety profile, with only one melanoma-related death out of all trial participants, and insights into comorbidities like cardiac disease and pulmonary fibrosis affecting older patients (0:02:42). The video highlights how clinical response rates often lag behind pathological ones, leaving scar tissue that takes time to clear, providing a deeper understanding of treatment outcomes (0:02:01).

Looking to the future, Dr. Kendra explores why desmoplastic melanoma could serve as a biomarker, allowing us to tailor therapies for specific subgroups—potentially avoiding unnecessary drug combinations and reducing toxicities while maintaining dramatic, long-lasting responses that have persisted for three years (0:03:52). We’ll discuss the potential of moving from single-drug to multi-drug approaches in cutaneous melanoma, but emphasize targeting less aggressive treatments for groups like desmoplastic melanoma patients (0:03:11).

Don’t miss these key moments:
0:00:00: Introduction to desmoplastic melanoma and high UV damage.
0:00:13: The role of inflammation in driving response rates.
0:00:22: Overview of resectable vs. unresectable cohorts.
0:00:39: Treatment differences based on disease stage and location.
0:00:59: Treatment duration plans and patient decisions on stopping.
0:01:31: Impressive 57% pathological complete response rate revealed.
0:01:49: Comparing clinical and pathological response rates.
0:02:20: Safety data—only one melanoma-related death in the trial.
0:03:11: Improving response rates in cutaneous melanoma with drug combinations.
0:04:00: Future directions—using desmoplastic melanoma as a biomarker.

Join us for this eye-opening journey into the future of melanoma treatment and immunotherapy innovations, presented by Kari L. Kendra, MD, PhD from The Ohio State University. Subscribe for more updates on cancer research, medical breakthroughs, and AACR 2025 highlights!

🔴 Subscribe and hit the bell for the latest in science and medicine!
💬 Have questions about melanoma or immunotherapy? Leave a comment below—we’d love to hear from you and discuss these advancements with Dr. Kendra’s insights!
#Melanoma #Immunotherapy #CancerResearch #DesmoplasticMelanoma #AACR2025 #LosAngeles #MedicalInnovation #KariLKendra #OhioStateUniversity